CMTM4抗体;CMTM4 Antibody—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P13145(CMTM4 Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

The CMTM4 (CKLF-like MARVEL transmembrane domain-containing protein 4) antibody is a tool used to study the function and expression of the CMTM4 protein, a member of the chemokine-like factor (CKLF) superfamily. CMTM4 is involved in immune regulation, cell signaling, and tumorigenesis. It is broadly expressed in human tissues, including immune cells, epithelial cells, and certain cancers. Research highlights its role in stabilizing PD-L1 (programmed death-ligand 1), a key immune checkpoint protein, by preventing its lysosomal degradation. This interaction links CMTM4 to tumor immune evasion and response to anti-PD-1/PD-L1 therapies.

Antibodies targeting CMTM4 are utilized in techniques like Western blot, immunohistochemistry (IHC), and immunofluorescence (IF) to detect protein levels, localization, and interactions in cell lines or clinical samples. Studies using these antibodies have revealed reduced CMTM4 expression in some cancers, correlating with poor prognosis or therapeutic resistance. Additionally, CMTM4 antibodies help explore its regulatory mechanisms in immune pathways, such as NF-κB signaling, and its crosstalk with other oncogenic molecules. Their applications extend to preclinical models to evaluate CMTM4 as a potential biomarker or therapeutic target in cancer immunotherapy and inflammatory diseases.